a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 26, 2001.

A. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166–2034:
1. Republic Bancorp, Inc., Louisville, Kentucky; to acquire 100 percent of the voting shares of Republic Bank and Trust Company of Indiana (in organization). Clarksville, Indiana.
2. American National Corporation (D. Michael Manies, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198–0001:
1. Republic Bancorp, Inc., Louisville, Kentucky; to acquire 100 percent of the voting shares of Republic Bank and Trust Company of Indiana (in organization). Clarksville, Indiana.
B. Federal Reserve Bank of Kansas City (Randall C. Sumner, Vice President) 925 Grand Avenue, Kansas City, Missouri 64198–0001:
1. American National Corporation, Omaha, Nebraska; to acquire 100 percent of the voting shares of American National Bank, Lincoln, Nebraska (in organization).
2. Colorado Business Bankshares, Inc., Denver, Colorado; to acquire 100 percent of the voting shares of First Capital Bank of Arizona, Phoenix, Arizona.

Jennifer J. Johnson
Secretary of the Board.
[FR Doc. 01–243 Filed 1–3–01; 8:45 am] BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225) to engage de novo, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 29, 2001.

A. Federal Reserve Bank of New York (Betsy Buttrill White, Senior Vice President) 33 Liberty Street, New York, New York 10045–0001:
1. Westdeutsche Landesbank Girozentrale, Dusseldorf, Germany; to acquire voting shares of Boullion Aviation Services, Inc., Bellevue, Washington, and thereby engage in leasing personal property or acting as agent, broker, or adviser in leasing such property, pursuant to § 225.28(b)(3) of Regulation Y; providing financial and investment advice pursuant to § 225.28(b)(6) of Regulation Y; making, acquiring, brokering or servicing loans or other extensions of credit, pursuant to § 225.28(b)(1) of Regulation Y; and engaging under contract with a third party in asset management, servicing and collection of assets of a type that an insured depository institution may originate and own, pursuant to § 225.28(b)(iv) of Regulation Y.

Jennifer J. Johnson
Secretary of the Board.
[FR Doc. 01–160 Filed 1–3–01; 8:45 am] BILLING CODE 6210–01–S

FEDERAL TRADE COMMISSION

[File No. 002 3194]
The Black & Decker Corporation, et al.; Analysis To Aid Public Comment
AGENCY: Federal Trade Commission.
ACTION: Proposed consent agreement.
SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices or unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the draft complaint that accompanies the consent agreement and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before January 29, 2001.

ADDRESSES: Comments should be directed to: FTC/Office of the Secretary, Room 159, 600 Pennsylvania Ave., NW., Washington, DC 20580.

FOR FURTHER INFORMATION CONTACT: Elaine Kolish or Laura Koss, FTC/S–4302, 600 Pennsylvania Ave., NW., Washington, DC 20580. (202) 326–3042 or 326–2890.

SUPPLEMENTARY INFORMATION: Pursuant to section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46 and section 2.34 of the Commission’s Rules of Practice (16 CFR 2.34), notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC Home Page (for December 28, 2000), on the World Wide Web, at http://www.ftc.gov/os/2000/12/index.htm. A paper copy can be obtained from the FTC Public Reference Room, Room H–130, 600 Pennsylvania Avenue, NW., Washington, DC 20580, either in person or by calling (202) 326–3627.

Public comment is invited. Comments should be directed to: FTC/Office of the Secretary, Room 159, 600 Pennsylvania Ave., NW., Washington, DC 20580. Two paper copies of each comment should be filed, and should be accompanied, if possible, by a 3½ inch diskette containing an electronic copy of the comment. Such comments or views will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with section 4.9(b)(6)(ii) of the Commission’s Rules of Practice (16 CFR 4.9(b)(6)(ii)).

Analysis of Proposed Consent Order To Aid Public Comment

The Federal Trade Commission has accepted an agreement, subject to final approval, to a proposed consent order from the respondents The Black & Decker Corporation and its wholly-owned subsidiary, Kwikset Corporation.
The proposed consent order has been placed on the public record for thirty (30) days for receipt of comments by interested persons. Comments received during this period will become part of the public record. After thirty (30) days, the Commission will again review the agreement and the comments received and will decide whether it should withdraw from the agreement and take other appropriate action or make final the agreement’s proposed order.

This matter concerns advertising, packaging, labeling, and promotional practices related to the sale of Kwikset Corporation’s lockset products, including locksets, deadbolts, knobs, and handles. The Commission’s complaint charges that respondents misrepresented on packaging and in advertising that certain Kwikset Corporation products are all or virtually all made in the United States. In truth and in fact, these products are actually made with significant foreign content and/or processing.

The proposed consent order contains a provision that is designed to remedy the charges and to prevent the respondents from engaging in similar acts and practices in the future. Part I of the proposed order prohibits Kwikset Corporation from misrepresenting the extent to which any Kwikset lockset is made in the United States. The order defines Kwikset lockset products as any product that is manufactured or sold by Kwikset Corporation that is used to secure doors, including but not limited to locksets, deadbolts, knobs, and handles. The proposed order would allow Kwikset Corporation to represent that such products are made in the United States as long as all, or virtually all, of the components of the products are of U.S. origin, and all, or virtually all, of the labor in manufacturing them is performed in the United States.

The proposed order also prohibits Kwikset Corporation from representing that its products are “All American Made” or “All American Made and Proud of it” or otherwise entirely made in the United States, unless such products are in fact 100% made in the United States.

Part II of the proposed order requires respondents to maintain materials relied upon in disseminating any representation covered by the order.

Part III of the proposed order requires Kwikset Corporation to distribute copies of the order to certain company officials and employees. Part IV of the proposed order requires the respondents to notify the Commission of any change in the corporation that may affect compliance obligations under the order. Part V of the proposed order requires the respondents to file one or more compliance reports. Part VI of the proposed order is a provision whereby the order, absent certain circumstances, terminates twenty years from the date of issuance.

The purpose of this analysis is to facilitate public comment on the proposed consent order. If is not intended to constitute an official interpretation of the agreement and proposed order or to modify in any way their terms.

By direction of the Commission.

Benjamin I. Berman,
Acting Secretary.

[FR Doc. 01–247 Filed 1–3–01; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 00N–1678]

Expansion of Medical Device Industry Initiatives

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing some changes in its standard practices for medical device, drug, food, and biologics inspections based on the outcome of the expansion of the medical device industry initiatives pilot program. FDA is discontinuing the practice of post-inspection notification letters for all inspections because the agency now provides inspected establishments with a copy of the establishment inspection report (EIR) when the inspection is deemed closed. FDA has decided to maintain pre-announced inspections and annotations of the inspectional observations (FDA 483) as standard practices for medical device inspections but with respect to inspections of other program areas, to apply these initiatives at the discretion of district management.

DATES: The changes to the medical device and expansion programs are effective January 1, 2001, with the publication of FDA’s 2001 edition of the Investigations Operations Manual (IOM). Written comments may be submitted at any time in accordance with FDA’s good guidance practices.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Denise D. Dion, Office of Regulatory Affairs (HFA–130), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–5645, FAX 301–443–6919.

SUPPLEMENTARY INFORMATION: During the FDA/medical device industry grassroots forums in 1995, several issues were discussed concerning FDA’s interaction with the medical device industry. A decision was made to consider action on three of the inspectional issues discussed. These included instituting: (1) Pre-announced inspections, (2) listing promised or completed corrective actions on FDA 483 items, and (3) post-inspection notification to establishments regarding their compliance status.

In fiscal year (FY) 1996, FDA initiated a pilot program for the medical device industry, implementing these three changes. The pilot program took place during the 1996 calendar year and was limited to inspections of medical device manufacturers that did not manufacture products that crossed other program areas such as drugs or biologics. Pre-announced inspections were offered to those medical device firms that met the criteria for inclusion in the pilot program. The criteria included nonviolative current good manufacturing practices inspectional histories and a history that records and individuals were available at earlier pre-announced inspections. FDA 483 annotations and the post-inspection notification were done for all medical device inspections whether or not the inspection was pre-announced.

Based on industry input, FDA initiated another year-long pilot program in January 1999, to provide similar coverage for program areas including drugs (both human and animal) and biologics. Food inspections were limited to FDA 483 annotations and post-inspection notification. In FY 2000, FDA considered the impact of the second pilot’s effects on field operations. The intent of the medical device pilot program was to optimize resource utilization, enhance FDA/industry communications, and provide firms prompt closure for nonviolative inspections and for corrected inspection observations. However, FDA determined that the additional burdens placed on field staff by the expansion into other program areas failed to capitalize resources and reduced overall field inspectional productivity.

FDA believes that the new inspection methodology will facilitate the medical device firms (the quality system inspection technique) implemented in October 1999 provides